Enhancing Cancer Immunorapy Via Activation of Innate Immunity

Seminars in Oncology

Volumn 42, Issue 4, 2015, Pages 562-572

  Goldberg, Jacob L ^a   Sondel, Paul M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CETUXIMAB; DINUTUXIMAB; GANGLIOSIDE GD2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOCYTOKINE; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; CANCER VACCINE;

ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; EFFECTOR CELL; GENETIC LINKAGE; HUMAN; IMMUNOSTIMULATION; INNATE IMMUNITY; MACROPHAGE; MEDICAL DECISION MAKING; MONOCYTE; NATURAL KILLER CELL; NEUROBLASTOMA; NEUTROPHIL; NEXT GENERATION SEQUENCING; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ADAPTIVE IMMUNITY; ANIMALS; CANCER VACCINES; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS;

EID: 84940380708     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.05.012     Document Type: Review

References (114)

1. M.M. Horowitz, R.P. Gale, P.M. Sondel, and et al. Graft-versus-leukemia reactions after bone marrow transplantation Blood 75 1990 555 562
2. J. Couzin-Frankel Breakthrough of year 2013. Cancer Immunor Science 342 2013 1432 1433
3. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 2011 1565 1570
4. T.L. Whiteside Inhibiting inhibitors: Evaluating agents targeting cancer immunosuppression Expert Opin Biol r 10 2010 1019 1035
5. C.L. Mackall, T.A. Fleisher, M.R. Brown, and et al. Lymphocyte depletion during treatment with intensive chemorapy for cancer Blood 84 1994 2221 2228
6. G.P. Dunn, L.J. Old, and R.D. Schreiber three Es of cancer immunoediting Annu Rev Immunol 22 2004 329 360
7. S. Kim, K. Iizuka, H.L. Aguila, I.L. Weissman, and W.M. Yokoyama In vivo natural killer cell activities revealed by natural killer cell-deficient mice Proc Natl Acad Sci U S A 97 2000 2731 2736
8. H.K. Jensen, F. Donskov, N. Marcussen, M. Nordsmark, F. Lundbeck, and H. von der Maase Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma J Clin Oncol 27 2009 4709 4717
9. M. Wislez, N. Rabbe, J. Marchal, and et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death Cancer Res 63 2003 1405 1412
10. A. Bellocq, M. Antoine, A. Flahault, and et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome Am J Pathol 152 1998 83 92
11. A.D. Gregory, and A.M. Houghton Tumor-associated neutrophils: New targets for cancer rapy Cancer Res 71 2011 2411 2416
12. A.M. Houghton, D.M. Rzymkiewicz, H. Ji, and et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth Nat Med 16 2010 219 223
13. E. Di Carlo, G. Forni, P. Lollini, M.P. Colombo, A. Modesti, and P. Musiani intriguing role of polymorphonuclear neutrophils in antitumor reactions Blood 97 2001 339 345
14. Z.G. Fridlender, J. Sun, S. Kim, and et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN Cancer Cell 16 2009 183 194
15. N.K. Cheung, I.Y. Cheung, B.H. Kushner, and et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission J Clin Oncol 30 2012 3264 3270
16. A. Mantovani, P. Allavena, and A. Sica Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression Eur J Cancer 40 2004 1660 1667
17. L. Ruggeri, M. Capanni, E. Urbani, and et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100
18. S.A. Rosenberg IL-2: First effective immunorapy for human cancer J Immunol 192 2014 5451 5458
19. A.L. Nelson, E. Dhimolea, and J.M. Reichert Development trends for human monoclonal antibody rapeutics Nat Rev Drug Discov 9 2010 767 774
20. K. Mujoo, D.A. Cheresh, H.M. Yang, and R.A. Reisfeld Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth Cancer Res 47 1987 1098 1104
21. N.K. Cheung, U.M. Saarinen, J.E. Neely, B. Landmeier, D. Donovan, and P.F. Coccia Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells Cancer Res 45 1985 2642 2649
22. G. Schulz, D.A. Cheresh, N.M. Varki, A. Yu, L.K. Staffileno, and R.A. Reisfeld Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients Cancer Res 44 1984 5914 5920
23. K. Kramer, W.L. Gerald, B.H. Kushner, S.M. Larson, M. Hameed, N.K. Cheung, and G. Disialoganglioside D2) loss following monoclonal antibody rapy is rare in neuroblastoma Clin Cancer Res 4 1998 2135 2139
24. N.K. Cheung, H. Lazarus, F.D. Miraldi, and et al. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma J Clin Oncol 5 1987 1430 1440
25. N.K. Cheung, B.H. Kushner, I.Y. Cheung, and et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age J Clin Oncol 16 1998 3053 3060
26. R. Handgretinger, P. Baader, R. Dopfer, and et al. A phase I study of neuroblastoma with anti-ganglioside GD2 antibody 14.G2a Cancer Immunol Immunor 35 1992 199 204
27. A.L. Yu, M.M. Uttenreur-Fischer, C.S. Huang, and et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma J Clin Oncol 16 1998 2169 2180
28. R. Handgretinger, K. Anderson, P. Lang, and et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma Eur J Cancer 31A 1995 261 267
29. J.L. Murray, J.E. Cunningham, H. Brewer, and et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors J Clin Oncol 12 1994 184 193
30. M.N. Saleh, M.B. Khazaeli, R.H. Wheeler, and et al. Phase I trial of chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma Hum Antibodies Hybridomas 3 1992 19 24
31. M.N. Saleh, M.B. Khazaeli, R.H. Wheeler, and et al. Phase I trial of murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma Cancer Res 52 1992 4342 4347
32. S.D. Yeh, S.M. Larson, L. Burch, and et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities J Nucl Med 32 1991 769 776
33. F. Navid, P.M. Sondel, R. Barfield, and et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma J Clin Oncol 32 2014 1445 1452
34. P. Reuland, L. Geiger, M.H. len, and et al. Follow-up in neuroblastoma: Comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and rapy response J Pediatr Hematol Oncol 23 2001 437 442
35. D.H. Munn, and N.K. Cheung Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma Cancer Res 47 1987 6600 6605
36. E. Barker, and R.A. Reisfeld A mechanism for neutrophil-mediated lysis of human neuroblastoma cells Cancer Res 53 1993 362 367
37. J.A. Hank, R.R. Robinson, J. Surfus, and et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo rapy with recombinant interleukin 2 Cancer Res 50 1990 5234 5239
38. J.D. Frost, J.A. Hank, G.H. Reaman, and et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of Children's Cancer Group Cancer 80 1997 317 333
39. M.R. Albertini, J.A. Hank, J.H. Schiller, and et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients Clin Cancer Res 3 1997 1277 1288
40. Z.C. Neal, J.C. Yang, A.L. Rakhmilevich, and et al. Enhanced activity of hu14.18-IL-2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 rapy Clin Cancer Res 10 2004 4839 4847
41. A.L. Gilman, M.F. Ozkaynak, K.K. Matthay, and et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from Children's Oncology Group J Clin Oncol 27 2009 85 91
42. M.F. Ozkaynak, P.M. Sondel, M.D. Krailo, and et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study J Clin Oncol 18 2000 4077 4085
43. K.K. Matthay, J.G. Villablanca, R.C. Seeger, and et al. Treatment of high-risk neuroblastoma with intensive chemorapy, radiorapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group N Engl J Med 341 1999 1165 1173
44. B.H. Kushner, K. Kramer, and N.K. Cheung Phase II trial of anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma J Clin Oncol 19 2001 4189 4194
45. I.Y. Cheung, M.S. Lo Piccolo, B.H. Kushner, and N.K. Cheung Early molecular response of marrow disease to biologic rapy is highly prognostic in neuroblastoma J Clin Oncol 21 2003 3853 3858
46. A.L. Yu, A.L. Gilman, M.F. Ozkaynak, and et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma N Engl J Med 363 2010 1324 1334
47. A. Hjelm Skog, P. Ragnhammar, J. Fagerberg, and et al. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma Cancer Immunol Immunor 48 1999 463 470
48. K.D. Khan, C. Emmanouilides, D.M. Benson Jr, and et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma Clin Cancer Res 12 2006 7046 7053
49. A. Mani, J. Roda, D. Young, and et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab Breast Cancer Res Treat 117 2009 83 89
50. R. Linke, A. Klein, and D. Seimetz Catumaxomab: Clinical development and future directions MAbs 2 2010 129 136
51. P. Schlegel, P. Lang, G. Zugmaier, and et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by rapy with T-cell engaging bispecific antibody blinatumomab Haematologica 99 2014 1212 1219
52. P.A. Moore, W. Zhang, G.J. Rainey, and et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma Blood 117 2011 4542 4551
53. M. Imboden, K.R. Murphy, A.L. Rakhmilevich, and et al. level of MHC class I expression on murine adenocarcinoma can change antitumor effector mechanism of immunocytokine rapy Cancer Res 61 2001 1500 1507
54. H.N. Lode, R. Xiang, T. Dreier, N.M. Varki, S.D. Gillies, and R.A. Reisfeld Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 rapy Blood 91 1998 1706 1715
55. S.D. Gillies, Y. Lan, S. Williams, and et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma Blood 105 2005 3972 3978
56. I.N. Buhtoiarov, Z.C. Neal, J. Gan, and et al. Differential internalization of hu14.18-IL-2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting J Leukoc Biol 89 2011 625 638
57. J.A. Gubbels, B. Gadbaw, I.N. Buhtoiarov, and et al. Ab-IL-2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to target cell-effector cell interface Cancer Immunol Immunor 60 2011 1789 1800
58. S. Shusterman, W.B. London, S.D. Gillies, and et al. Antitumor activity of hu14.18-IL-2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study J Clin Oncol 28 2010 4969 4975
59. T. List, and D. Neri Immunocytokines: A review of molecules in clinical development for cancer rapy Clin Pharmacol 5 2013 29 45
60. D.C. Delgado, J.A. Hank, J. Kolesar, and et al. Genotypes of NK cell KIR receptors, ir ligands, and Fcgamma receptors in response of neuroblastoma patients to Hu14.18-IL-2 immunorapy Cancer Res 70 2010 9554 9561
61. N. Tarek, J.B. Le Luduec, M.M. Gallagher, and et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment J Clin Invest 122 2012 3260 3270
62. M.J. Wilson, M. Torkar, A. Haude, and et al. Plasticity in organization and sequences of human KIR/ILT gene families Proc Natl Acad Sci U S A 97 2000 4778 4783
63. M. Uhrberg, N.M. Valiante, B.P. Shum, and et al. Human diversity in killer cell inhibitory receptor genes Immunity 7 1997 753 763
64. L. Ruggeri, A. Mancusi, E. Burchielli, and et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation Blood Cells Mol Dis 40 2008 84 90
65. W. Leung, R. Iyengar, V. Turner, and et al. Determinants of antileukemia effects of allogeneic NK cells J Immunol 172 2004 644 650
66. W. Leung, R. Handgretinger, R. Iyengar, V. Turner, M.S. Holladay, and G.A. Hale Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma Br J Cancer 97 2007 539 542
67. K.C. Hsu, C.A. Keever-Taylor, A. Wilton, and et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Blood 105 2005 4878 4884
68. J.M. Venstrom, J. Zheng, N. Noor, and et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma Clin Cancer Res 15 2009 7330 7334
69. S. Cooley, D.J. Weisdorf, L.A. Guethlein, and et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia Blood 116 2010 2411 2419
70. D. Pende, S. Marcenaro, M. Falco, and et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: Evaluation of functional role of activating KIR and redefinition of inhibitory KIR specificity Blood 113 2009 3119 3129
71. H.E. Kohrt, A. Thielens, A. Marabelle, and et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monorapy and in combination with anti-CD20 antibodies Blood 123 2014 678 686
72. F. Aranda, E. Vacchelli, A. Eggermont, and et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancer rapy Oncoimmunology 3 2014 e27297
73. K.C. Conlon, E. Lugli, H.C. Welles, and et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer J Clin Oncol 33 2014 74 82
74. S. Huang, L. Mills, B. Mian, and et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma Am J Pathol 161 2002 125 134
75. J. Xu, J. Escamilla, S. Mok, and et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves efficacy of radiorapy in prostate cancer Cancer Res 73 2013 2782 2794
76. Phase 1 study of IMC-CS4, a monoclonal antibody targeted to CSF-1 receptor (CSF-1R), in subjects with advanced solid tumors refractory to standard rapy or for which no standard rapy is available. Eli Lilly. 2011. Available from: http://clinicaltrials.gov/show/NCT01346358.
77. Open-label, multicenter, dose escalation phase Ia/Ib study with expansion phase to evaluate safety, pharmacokinetics and activity of RO5509554, administered as an intravenous infusion as monorapy and in combination with paclitaxel in patients with advanced solid tumors. Hoffmann-LaRoche. 2011. Available from: http://clinicaltrials.gov/show/NCT01494688.
78. A phase 1 study to assess safety, pharmacokinetics, and pharmacodynamics of PLX3397 in patients with advanced, incurable, solid tumors in which target kinases are linked to disease pathophysiology. Plexxikon. 2009. Available from: http://clinicaltrials.gov/show/NCT01004861.
79. A phase 1/2 safety and efficacy study of orally administered PLX3397 in adults with relapsed or refractory acute myeloid Leukemia (AML). Plexxikon. 2011. Available from: http://clinicaltrials.gov/show/NCT01349049.
80. A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. Plexxikon. 2011. Available from: http://clinicaltrials.gov/show/NCT01349036.
81. A phase 1b study to assess safety of PLX3397 and paclitaxel in patients with advanced solid tumors. Plexxikon. 2012. Available from: http://clinicaltrials.gov/show/NCT01525602.
82. Enhancing efficacy of chemorapy in triple negative/basal-like breast cancer by targeting macrophages: A multicenter phase Ib/II study of PLX 3397 and eribulin in patients with metastatic breast cancer. Plexxikon. 2012. Available from: http://clinicaltrials.gov/show/NCT01596751.
83. An open label phase 1b/2 study of orally administered PLX3397 in combination with radiation rapy and temozolomide in patients with newly diagnosed glioblastoma. Plexxikon. 2012. Available from: http://clinicaltrials.gov/show/NCT01790503.
84. A phase 1b open label, dose escalation study to assess safety, pharmacokinetics, pharmacodynamics, and antitumor activity of PLX3397 in combination with vemurafenib in V600-mutated BRAF unresectable or metastatic melanoma. Plexxikon. 2013. Available from: http://clinicaltrials.gov/show/NCT01826448.
85. L. Galluzzi, L. Senovilla, L. Zitvogel, and G. Kroemer secret ally: immunostimulation by anticancer drugs Nat Rev Drug Discov 11 2012 215 233
86. A.L. Rakhmilevich, I.N. Buhtoiarov, M. Malkovsky, and P.M. Sondel CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors Cancer Immunol Immunor 57 2008 1151 1160
87. T.J. Van De Voort, M.A. Felder, R.K. Yang, P.M. Sondel, and A.L. Rakhmilevich Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice J Immunor 36 2013 29 40
88. K.L. Alderson, M. Luangrath, M.M. Elsenheimer, and et al. Enhancement of anti-melanoma response of Hu14.18K322A by alphaCD40+CpG Cancer Immunol Immunor 62 2013 665 675
89. L. Galluzzi, E. Vacchelli, A. Eggermont, and et al. Trial watch: Experimental Toll-like receptor agonists for cancer rapy Oncoimmunology 1 2012 699 716
90. M.P. Link, A.M. Goorin, A.W. Miser, and et al. effect of adjuvant chemorapy on relapse-free survival in patients with osteosarcoma of extremity N Engl J Med 314 1986 1600 1606
91. E.S. Kleinerman Biologic rapy for osteosarcoma using liposome-encapsulated muramyl tripeptide Hematol Oncol Clin North Am 9 1995 927 938
92. P.A. Meyers, C.L. Schwartz, M.D. Krailo, and et al. Osteosarcoma: Addition of muramyl tripeptide to chemorapy improves overall survival - a report from Children's Oncology Group J Clin Oncol 26 2008 633 638
93. I.N. Buhtoiarov, H. Lum, G. Berke, D.M. Paulnock, P.M. Sondel, and A.L. Rakhmilevich CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro J Immunol 174 2005 6013 6022
94. H.D. Lum, I.N. Buhtoiarov, B.E. Schmidt, and et al. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha Immunology 118 2006 261 270
95. H.D. Lum, I.N. Buhtoiarov, B.E. Schmidt, and et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages J Leukoc Biol 79 2006 1181 1192
96. I.N. Buhtoiarov, H.D. Lum, G. Berke, P.M. Sondel, and A.L. Rakhmilevich Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects J Immunol 176 2006 309 318
97. I.N. Buhtoiarov, P.M. Sondel, J.M. Wigginton, and et al. Anti-tumour synergy of cytotoxic chemorapy and anti-CD40 plus CpG-ODN immunorapy through repolarization of tumour-associated macrophages Immunology 132 2011 226 239
98. G.L. Beatty, E.G. Chiorean, M.P. Fishman, and et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
99. S.R. Woo, L. Corrales, and T.F. Gajewski Innate immune recognition of cancer Annu Rev Immunol 33 2015 445 474
100. P.C. Klohn, U. Wuellner, N. Zizlsperger, and et al. IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody rapeutics international conferences and 2012 Annual Meeting of Antibody Society: December 3-6, 2012, San Diego, CA MAbs 5 2013 178 201
101. M.R. Albertini, J.A. Hank, and P.M. Sondel Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma Cancer Chemor Biol Response Modif 22 2005 789 797
102. B.H. Yamane, J.A. Hank, M.R. Albertini, and P.M. Sondel development of antibody-IL-2 based immunorapy with hu14.18-IL-2 (EMD-273063) in melanoma and neuroblastoma Expert Opin Investig Drugs 18 2009 991 1000
103. E. Luedke, A.C. Jaime-Ramirez, N. Bhave, and W.E. Carson III Monoclonal antibody rapy of pancreatic cancer with cetuximab: Potential for immune modulation J Immunor 35 2012 367 373
104. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
105. Y.C. Lu, X. Yao, J.S. Crystal, and et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions Clin Cancer Res 20 2014 3401 3410
106. E. Tran, S. Turcotte, A. Gros, and et al. Cancer immunorapy based on mutation-specific CD4+T cells in a patient with epilial cancer Science 344 2014 641 645
107. A. Marabelle, H. Kohrt, C. Caux, and R. Levy Intratumoral immunization: A new paradigm for cancer rapy Clin Cancer Res 20 2014 1747 1756
108. H.E. Kohrt, R. Houot, M.J. Goldstein, and et al. CD137 stimulation enhances antilymphoma activity of anti-CD20 antibodies Blood 117 2011 2423 2432
109. H.E. Kohrt, A.D. Colevas, R. Houot, and et al. Targeting CD137 enhances efficacy of cetuximab J Clin Invest 124 2014 2668 2682
110. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
111. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
112. O. Hamid, C. Robert, A. Daud, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2013 134 144
113. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
114. J.M. Weiss, J.J. Subleski, T. Back, and et al. Regulatory T cells and myeloid-derived suppressor cells in tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 rapy J Immunol 192 2014 5821 5829